Zacks Investment Research upgraded shares of SYNERGETICS USA (SURG) from UNDERPERFORM to NEUTRAL on December 03, 2013, with a target price of $4.20.
Synergetics designs,manufactures and markets medical devices for use primarily in ophthalmic surgery and neurosurgery and for other healthcare applications. Its products are designed and manufactured to support micro or minimally invasive surgical procedures.In addition to its surgical devices and equipment,it designs and manufactures disposable and non-disposable supplies and accessories for use with such devices and equipment.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SYNERGETICS USA (SURG),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment